NASDAQ · Financial Statements
Aileron Therapeutics, Inc. (ALRN) Financial Statements
$2.11
NASDAQ: ALRN
Market Cap $45.72M
Overview Financials Dividend
Aileron Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $50.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $0 $0 $0 $0 $0 Operating Profit $-27.0M $-28.0M $-16.0M $-65.0M $-51.0M Net Profit $-26.0M $-27.0M $-16.0M $-63.0M $-50.0M EPS $-5.80 $-5.95 $-3.42 $-3.51 $-1.96 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $48.0M $22.0M $106.0M $62.0M $24.0M Total Liabilities $5.0M $3.0M $99.0M $8.0M $7.0M Cash $4.0M $5.0M $17.0M $13.0M $3.0M Borrowings $0 $0 $0 $0 $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $-24.0M $-25.0M $-20.0M $-22.0M $-19.0M Investing Cash Flow $-36.0M $26.0M $16.0M $0 $0 Financing Cash Flow $0 $0 $16.0M $7.0M $10.0M Net Cash Flow $-4.0M $2.0M $12.0M $-4.0M $-10.0M Free Cash Flow $-24.0M $-25.0M $-20.0M $-22.0M $-19.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.02 EV / EBITDA -1.04 FCF Yield -36.33% Quick Ratio 0.40 Interest Coverage — Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .